CN112807342A - Dalbergia wood composition and application thereof - Google Patents
Dalbergia wood composition and application thereof Download PDFInfo
- Publication number
- CN112807342A CN112807342A CN202110027811.0A CN202110027811A CN112807342A CN 112807342 A CN112807342 A CN 112807342A CN 202110027811 A CN202110027811 A CN 202110027811A CN 112807342 A CN112807342 A CN 112807342A
- Authority
- CN
- China
- Prior art keywords
- dalbergia wood
- composition
- salvia miltiorrhiza
- dalbergia
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002023 wood Substances 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 241000522195 Dalbergia Species 0.000 title description 42
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000341 volatile oil Substances 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000004821 distillation Methods 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 244000138993 panchioli Species 0.000 claims abstract 14
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 9
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 2
- 230000002137 anti-vascular effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 abstract description 22
- 230000006907 apoptotic process Effects 0.000 abstract description 17
- 238000002474 experimental method Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 239000007788 liquid Substances 0.000 abstract description 6
- 240000007164 Salvia officinalis Species 0.000 abstract description 5
- 235000005412 red sage Nutrition 0.000 abstract description 5
- 210000004295 hippocampal neuron Anatomy 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 210000003710 cerebral cortex Anatomy 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract 2
- 239000006286 aqueous extract Substances 0.000 abstract 1
- 238000004817 gas chromatography Methods 0.000 abstract 1
- 238000012827 research and development Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 35
- 239000000243 solution Substances 0.000 description 27
- 244000132619 red sage Species 0.000 description 21
- 108700000707 bcl-2-Associated X Proteins 0.000 description 16
- 102000055102 bcl-2-Associated X Human genes 0.000 description 16
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 13
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 13
- 108090000397 Caspase 3 Proteins 0.000 description 13
- 102100029855 Caspase-3 Human genes 0.000 description 13
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 13
- 108091007960 PI3Ks Proteins 0.000 description 13
- 108091008611 Protein Kinase B Proteins 0.000 description 13
- 244000086363 Pterocarpus indicus Species 0.000 description 13
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 13
- 102000004039 Caspase-9 Human genes 0.000 description 12
- 108090000566 Caspase-9 Proteins 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 6
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 6
- 241000657528 Dalbergia odorifera Species 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012347 Morris Water Maze Methods 0.000 description 5
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 5
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 3
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 3
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 3
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006909 anti-apoptosis Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 229960003371 protocatechualdehyde Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 3
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 3
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000031836 visual learning Effects 0.000 description 3
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000006667 mitochondrial pathway Effects 0.000 description 2
- 230000019581 neuron apoptotic process Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- FQTLCLSUCSAZDY-SDNWHVSQSA-N (6E)-nerolidol Chemical compound CC(C)=CCC\C(C)=C\CCC(C)(O)C=C FQTLCLSUCSAZDY-SDNWHVSQSA-N 0.000 description 1
- FQTLCLSUCSAZDY-SZGZABIGSA-N (E)-Nerolidol Natural products CC(C)=CCC\C(C)=C/CC[C@@](C)(O)C=C FQTLCLSUCSAZDY-SZGZABIGSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000002267 nissl body Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- ZLWGOLLBNDIBMM-UHFFFAOYSA-N trans-nerolidol Natural products CC(C)C(=C)C(O)CCC=C(/C)CCC=C(C)C ZLWGOLLBNDIBMM-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a dalbergia wood composition and application thereof, belonging to the field of traditional Chinese medicine research and development. The dalbergia wood composition is prepared by extracting dalbergia wood volatile oil by a water distillation method, extracting an aqueous extract of a red sage root medicinal material by a reflux extraction method, and mixing the dalbergia wood volatile oil with a red sage root liquid. The quality control of lignum Dalbergiae Odoriferae and the quality control of Saviae Miltiorrhizae radix by gas chromatography are performed. Animal experiments prove that the dalbergia wood composition has the efficacy activity of preventing and treating vascular dementia, and the possible mechanism is to reduce the apoptosis of nerve cells to protect cerebral cortex and hippocampal neuron cells of a rat with vascular dementia.
Description
Technical Field
The invention belongs to the technical field of preparation of traditional Chinese medicine formulas, and particularly relates to a composition of dalbergia wood and salvia miltiorrhiza and application thereof.
Background
Vascular Dementia (VaD) refers to the qualitative and functional changes of cerebral vessels caused by cerebral ischemia, cerebral hemorrhage or hemorrhagic brain tissue damage, acute and chronic ischemia and hypoxia, mainly the impairment of memory and cognitive function, and the accompanying speech, movement, visual space disorder and personality disorder. Epidemiological investigations show that: vascular dementia is the second most common cause of dementia following Alzheimer's Disease (AD), with a 3.9% incidence of dementia in older adults over 65 years of age in china, with vascular dementia as high as 68.5% occurring. The average life age of vascular dementia is only 4-6 years.
Vascular dementia is a type of dementia which can be prevented and treated, and the early treatment has certain reversibility. However, vascular dementia is a multifactorial process, the etiology is complex, the exact pathogenesis is not clear, and an effective therapeutic drug is lacked.
At present, fewer drugs are used for treating vascular dementia, galantamine and donepezil are common cholinesterase blockers, galantamine has no obvious improvement effect on patients with simple vascular dementia, and can be used for treating patients with vascular dementia complicated with Alzheimer disease, and donepezil can improve the cognition and the overall function of the patients to a certain extent. Therefore, it is necessary to develop a Chinese patent medicine for treating vascular dementia, to treat vascular dementia at an early stage, and to avoid the decline of cognitive function and memory function of a patient with vascular dementia, so as to achieve the purpose of treating vascular dementia. The red sage root and the dalbergia wood are a traditional medicine pair, the red sage root has the functions of activating blood circulation to dissipate blood stasis, stimulating the menstrual flow and relieving pain, and the red sage root enters heart channels and liver channels, and the dalbergia wood has the functions of dissipating blood stasis, stopping bleeding, regulating qi and relieving pain. After being combined with Danshen root, Dalbergia wood can induce resuscitation with aromatics and induce the drugs to enter meridians.
Disclosure of Invention
The invention aims to provide a rosewood heart wood composition and application thereof. The content of the application mainly comprises the weight ratio of the dalbergia wood and the salvia miltiorrhiza medicine and the application thereof.
The purpose of the invention is realized by the following technical scheme:
the invention provides a dalbergia wood composition, which comprises the following raw material medicines in parts by weight: 10-30 g of dalbergia wood and 10-30 g of salvia miltiorrhiza.
The invention provides a preparation method of a dalbergia wood composition, which comprises the steps of taking 10-30 g of dalbergia wood medicinal materials and 10-30 g of salvia miltiorrhiza, crushing the dalbergia wood medicinal materials, and extracting dalbergia wood volatile oil by a water distillation method; crushing a salvia miltiorrhiza medicinal material, adding water which is 2-5 times of the weight of the salvia miltiorrhiza, soaking for 1-3 hours, performing reflux extraction for 1-3 times at 90-100 ℃, combining extracting solutions, concentrating, mixing the dalbergia wood volatile oil and the salvia miltiorrhiza liquid, and adding polysorbate 80 with the volume ratio of 2-5% to obtain the traditional Chinese medicine composition, wherein each milliliter of the solution is equivalent to 1-3 g of the crude drug of the dalbergia wood, and 1-3 g of the crude drug of the salvia miltiorrhiza.
The rosewood heart wood; the main components of Saviae Miltiorrhizae radix include danshensu, protocatechualdehyde, rosmarinic acid and salvianolic acid B.
Animal experiments prove that the dalbergia wood composition has obvious prevention and treatment effects on a vascular dementia model of a rat. Pharmacodynamic experiment results show that by adopting a Morris water maze experimental method, the lignum dalbergiae odoriferae composition can promote the spatial learning and memory ability of rats with vascular dementia; shortening the swimming latency and total swimming distance of the vascular dementia rats, increasing the quadrant distance percentage of the platform, increasing the number of Nissl (Nissl) bodies and reducing the apoptosis of neurons.
Damage to neuronal cells in the brain of patients with VaD can lead to a loss of memory. Apoptosis of nerve cells is a major cause of neuronal cell damage in the brain. Apoptosis is the process of cell death, which is called programmed cell death, because some gene of cell is activated, and cell is actively and gradually killed according to a certain program. Apoptosis is also an essential process for the elimination of damaged cells in the process of maintaining cellular homeostasis and progression. Because of the limited ability of central nervous system neurons to proliferate and regenerate, reducing neuronal apoptosis is a major goal in protecting the VaD cerebral cortex and hippocampal neurons.Bcl-2(B-cell lymphoma2) Bcl-2 protein family is an indispensable system in the regulation program of apoptosis, and Bcl-2 regulates and controls the apoptosis of mitochondria, acts on the upstream of Caspase-3, inhibits the release of cytochrome C and the like from the mitochondria, and plays an anti-apoptosis effect. When Bcl-2 is highly expressed, the Bcl-2 can form heterodimer Bcl-2/Bax with apoptosis factor Bax, the heterodimer has the effect of inhibiting Bax/Bax homodimer from inducing apoptosis, a PI3K/Akt signal pathway is one of apoptosis pathways, the PI3K signal pathway can improve the cell viability, inhibit cell senescence and death and the like, after PI3K is activated, Akt activation can be induced, and the activated Akt is transferred from cytoplasm to a cell membrane and provides an anchoring site for recruiting PI3K translocation to the membrane to participate in signal transduction. Apoptosis can also occur via the mitochondrial pathway, the Caspase family[68]Mainly involved in mitochondrial pathways, of which Caspase 3, Caspase-9 are one of the most important downstream effectors of apoptosis. In the VaD neurodegenerative process, Caspase 3 and Caspase-9 activity can be inhibited to generate a neuroprotective effect.
The dalbergia wood composition can reduce Bax expression and increase Bcl-2 expression, so that Bcl-2/Bax ratio is increased, apoptosis of cells is inhibited, the Bax expression level of a VaD model group is obviously up-regulated, the expression level of Bcl-2 factors is reduced, so that Bax/Bcl-2 ratio is higher, and neuronal cells are induced to undergo apoptosis. The protective effect of the dalbergia wood composition on VaD is realized by up-regulating Bcl-2 and down-regulating Bax expression to protect neuronal cells. The rosewood composition can increase the expression of PI3K and Akt protein and reduce the content of Caspase 3 and Caspase-9 protein. The suggestion shows that the rosewood heart wood composition can inhibit the expression of Caspase 3 and Caspase-9 by activating a PI3K/Akt signal channel, thereby reducing the apoptosis of neuron cells.
Drawings
FIG. 1 is a high performance liquid chromatogram of lignum Dalbergiae Odoriferae volatile oil in lignum Dalbergiae Odoriferae composition;
FIG. 2 is a high performance liquid chromatogram of an aqueous solution of Salvia miltiorrhiza Bunge in a composition of lignum Dalbergiae Odoriferae;
FIG. 3 shows the results of the Morris water maze test for testing the effect of the lignum Dalbergiae Odoriferae composition on the spatial learning and memory ability of rats with vascular dementia;
FIG. 4 is a graph showing the results of HE staining, 1. normal group, 2. model group, and 3. lignum Dalbergiae Odoriferae composition group;
FIG. 5 is a graph showing the results of Niger's staining, 1. normal group, 2. model group, and 3. Dalbergia Odorifera composition group;
FIG. 6 shows the effect of the Dalbergia Odorifera composition group on the expression of Caspase-3 and Caspase-9 proteins in the VaD model rat, 1. normal group, 2. model group, and 3. Dalbergia odorifera composition group;
FIG. 7 Effect of Dalbergia Odorifera composition group on the expression of Bax, Bcl-2 proteins in VaD model rats;
FIG. 8 Effect of Dalbergia Odorifera composition on VaD model rat PI 3K/Akt;
Detailed Description
The following examples further illustrate the invention but are not intended to limit the invention.
Example 1
Respectively crushing 10 g of dalbergia wood medicinal material and 10 g of salvia miltiorrhiza medicinal material, extracting dalbergia wood volatile oil by a water distillation method, and separating 1ml of volatile oil suspension; taking a salvia miltiorrhiza medicinal material, adding 50ml of water, soaking for 1 hour, carrying out reflux extraction for 2 times at 90 ℃, combining extracting solutions, concentrating to 9ml, mixing the dalbergia wood volatile oil and the salvia miltiorrhiza liquid, and adding 0.5 g of polysorbate 80 to obtain the traditional Chinese medicine, wherein each ml of solution is equivalent to 1g of crude dalbergia wood and 1g of crude salvia miltiorrhiza.
Example 2
Respectively crushing 20 g of dalbergia wood medicinal material and 30 g of salvia miltiorrhiza medicinal material, extracting dalbergia wood volatile oil by a water distillation method, and separating 1ml of volatile oil suspension; taking a salvia miltiorrhiza medicinal material, adding 90ml of water, soaking for 2 hours, carrying out reflux extraction for 1 time at 100 ℃, taking an extracting solution, concentrating to 9ml, mixing the dalbergia wood volatile oil and the salvia miltiorrhiza liquid, and adding 0.2 g of polysorbate 80 to obtain the traditional Chinese medicine, wherein each ml of the solution is equivalent to 2g of crude dalbergia wood and 3g of crude salvia miltiorrhiza.
Example 3
Respectively crushing 30 g of dalbergia wood medicinal material and 20 g of salvia miltiorrhiza medicinal material, extracting dalbergia wood volatile oil by a water distillation method, and separating 1ml of volatile oil suspension; taking salvia miltiorrhiza, adding 40ml of water, soaking for 3 hours, carrying out reflux extraction for 3 times at 100 ℃, combining extracting solutions, concentrating to 9ml, mixing the dalbergia wood volatile oil and the salvia miltiorrhiza solution, and adding 0.75 g of polysorbate 80 to obtain the traditional Chinese medicine, wherein each ml of solution is equivalent to 3g of crude drug of dalbergia wood and 2g of crude drug of salvia miltiorrhiza.
Example 4
Content determination of dalbergia wood in dalbergia wood composition
Agilent 7890A gas chromatograph (Agilent, usa); chromatography column HP-INNOWAX (column length 30m, internal diameter 0.32mm, membrane thickness 0.25 mm); a FID detector; carrier gas: nitrogen gas; temperature programming: the initial temperature was 100 ℃ for 5 minutes, the temperature was raised to 160 ℃ at a rate of 5 ℃ per minute for 7 minutes, and then to 230 ℃ at a rate of 5 ℃ per minute for 2 minutes. Sample inlet temperature: 230 ℃, carrier gas flow rate: 3 ml/min.
Control solutions were prepared by dissolving the inverted nerolidol control (88.3% pure, available from Sigma) in n-hexane.
Preparing a test solution, precisely measuring 2ml of the dalbergia wood composition solution, adding 20ml of n-hexane for extraction, taking n-hexane solution, evaporating to dryness at low temperature, and metering volume with n-hexane to 2ml of a measuring bottle to obtain the test solution shown in figure 1.
The results show that the content of the trans-nerolidol in 6 batches of the rosewood composition solution is 8.2-31.5 (mu g/ml).
Example 8
Content determination of dalbergia root in dalbergia wood composition
Ultra high performance liquid chromatography (Waters, usa), Empower workstation (Waters, usa); a chromatographic column: sigma Ascentis Express C18(100 mm. times.2.1 mm, 2.7 μm); mobile phase: acetonitrile (A) -0.1% formic acid (B), and gradient elution is carried out for 0-3 min, wherein the concentration of A is 5%; 5-13% of A for 3-9 min; 13-25% of A for 9-18 min; column temperature: 35 ℃; detection wavelength: 280 nm; flow rate: 0.6 ml/min; sample introduction amount: 3 μ l.
Preparing a reference substance solution, namely purchasing a danshensu sodium reference substance (with the purity of 98.1%), a protocatechuic aldehyde reference substance (with the purity of 98.2%), a rosmarinic acid reference substance (with the purity of 99.8%) and a salvianolic acid B reference substance (with the purity of 95.4%) from a Chinese institute for testing and determining medicinal and biological products; the resulting solution was dissolved in 50% methanol to prepare a mixed control solution.
Preparing a test solution, precisely measuring 4ml of the dalbergia wood composition solution, placing the solution in a 50ml measuring flask, adding 50% methanol to the scale, and shaking up to obtain the test solution shown in figure 2.
The result shows that the content of the danshensu sodium in 6 batches of the dalbergia wood composition solution is 1.2-3.6 (mg/ml); the protocatechuic aldehyde content is 0.2-0.6 (mg/ml); the content result of the rosmarinic acid is 0.08-0.24 (mg/ml); the content of salvianolic acid B is 0.45-1.15 (mg/ml).
Example 9
Preparation of VaD rat model A VaD rat model was prepared by permanent ligation of bilateral common carotid arteries. The experiment adopts a two-blood vessel blocking method (2-VO) to establish a VaD rat model, and the principle is that after the bilateral common carotid arteries are permanently ligated, incomplete cerebral ischemia can be caused, chronic cerebral tissue hypoperfusion is caused, and ischemia and hypoxia injury can be caused to the brain and the like. 2-VO is an effective rat model making method for simulating a VaD pathogenesis, and the model is applied more at home and abroad and is one of the more recognized VaD models;
the VaD rats are divided into model groups, and randomly divided into a pseudo-operation group, a model group, a nimodipine group (3mg/kg), a gold group (12mg/kg) and a rosewood composition group (the dosage is 40g/kg, 32g/kg or 16g/kg), orally administered once a day for 21 days continuously until the behavioral test of the rats is finished.
The Morris water maze experiment of the rat, the positioning navigation experiment, and the experiment are carried out for 5 days, and the rat needs to be familiar with the environment on the first day and is allowed to swim freely for about 2 minutes. The platform of the Morris water maze is arranged at the middle point of the fourth quadrant, a rat is placed into water from the opposite quadrant at a fixed position, the rat needs to be back to the platform, the collection time is 120s in Total, the Escape Latency (Escape Latency) and the Total swimming Distance (Total Distance) of the rat are recorded by a video tracking analysis system, and data are subjected to statistical analysis. The experimental result shows that from the fourth day, the dalbergia wood composition group, the gold groups can obviously shorten the swimming latency and the total swimming route, and the nimodipine group can shorten the swimming latency and the total swimming route of the model rat at the fifth day (P is less than 0.01). And (3) a space exploration experiment, namely removing the platform on the sixth day of the Morris experiment, enabling the experimental rat to enter water at the same water inlet point, freely swimming for 120s, and recording the number of times that the experimental rat passes through the platform area in 120s and the residence time of the quadrant of the platform. The space exploration experiment result shows that the percentage of the route of the rats in the VaD model group in the quadrant of the original platform is obviously reduced (p is less than 0.05) compared with the rats in the sham operation group; the rosewood composition group, gold groups and nimodipine group significantly increased the percentage of swimming distance in the platform quadrant of rats (. about.p <0.05) compared to the model group.
Morris water maze experimental study finds that the dalbergia wood composition group has a promoting effect on the spatial learning and memory ability of VaD rat mice.
Example 10
Effect of lignum Dalbergiae Odoriferae composition on brain histopathology experiment of VaD rats
After the rat behavioral experiment was completed, 7 rats were taken out of each group, whole brains were removed, fixed in 4% paraformaldehyde at 4 ℃, dehydrated with alcohol, transparent with xylene, embedded in paraffin, and sliced to a thickness of 5 μm for histopathological examination. Paraffin sections were subjected to conventional HE staining and Nissl (Nissl) staining.
The HE staining result shows that the nerve cells of the visible under-mirror pseudo-operation group are orderly arranged, gaps are not abnormal, the tissue structure around the cells is complete, the cell nucleus is clear, the nucleolus is obvious, the cytoplasm is uniformly stained, and the cell membrane is complete; the model group had disorganized nerve cell arrangement, edema. Pale staining, the chromatin in the pycnotic nuclei agglutinates into clumps. The rosewood composition group has orderly arranged nerve cells, tightly arranged pyramidal cells, increased number of neuron cell layers and recovery of nerve synapses of part of neuron cells, as shown in figure 4.
The apoptosis condition of the neuron cells is reflected by the result of Niger staining, the neuron cells of the visible under-mirror pseudo-operation group are orderly arranged, the neuron cell structure is clear and complete, and the Niger body is in a blue granular shape and is relatively rich; the neuron cell structure of the model group is obviously changed, the karyotype is irregular, the chromatin in the nucleus is collected, and the nissl is obviously reduced, which indicates that the nerve cells are apoptotic. The number of hippocampal neuron cells and the number of nissl body of the rats are increased and the structure is clear in each administration group of the dalbergia wood composition, which shows that the dalbergia wood composition has the function of protecting the neuron cells of the rats of the VaD model, and the figure is 5; nissl staining statistical results show that compared with a sham operation group, the number of neuron cells in a model group is obviously reduced, and the neuron cells have significant difference (P < 0.01); compared with the model group, the rosewood heart wood composition group can improve the survival rate of the cells of the hippocampal neurons of the VaD rats and has a significant difference (P < 0.01).
Example 11
Effect of lignum Dalbergiae Odoriferae composition group on expression of Caspase-3 and Caspase-9 proteins in VaD model rat
(1) Extraction of proteins
After the behavioral experiments of rats are finished, 5 rats in each group are respectively taken, 10% chloral hydrate (350mg/kg) is injected into the abdominal cavity for anesthesia, the head is broken, the brain is taken out, the taken brain is placed on clean filter paper, the filter paper is placed on ice, the hippocampus is quickly separated, tissue lysate is added, and the weight ratio of the added tissue lysate to the added tissue lysate is 5: 1, freezing in a refrigerator at the temperature of 20 ℃ below zero, homogenating by a tissue homogenizer, and carrying out ice bath for 30min after homogenating. Centrifuging the sample at 14000g of revolution at 4 deg.C for 20min, collecting supernatant, quantifying, packaging, and storing in-80 deg.C refrigerator;
(2) determination of protein concentration
The BCA method was used for the assay. Adding BCA working solution into a protein standard BSA (bovine serum albumin) solution with the concentration of 0.5mg/mL to prepare a series of standard curve solutions, preparing a test sample by the same method, and measuring the absorbance of each hole at the wavelength of 490nm by using an enzyme-labeling instrument;
(3) preparation of sodium dodecyl sulfate-Polyacrylamide gel (SDS-PAGE)
The glue making procedure is as follows: and (5) installing the glass plate. Preparing 12% separating glue solution, mixing, immediately injecting into the gap of glass plate, sealing with deionized water for 60min, adding 5% concentrated glue solution, inserting into comb, sealing, and polymerizing for 60 min. Storing at 4 deg.C;
(4) conditions of electrophoresis
According to the result of protein quantification by the BCA method, adjusting the volume of each sample before loading to make the total amount of each group of proteins consistent, adding 5 xSDS-PAGE protein loading buffer solution, carrying out denaturation by boiling water bath, loading, wherein the starting voltage is 80V, when the sample enters the separation gel from the concentration gel, the voltage is increased to 180V, and when the indicator runs to the bottom of the separation gel, the electrophoresis is stopped;
(5) rotary die
The gel was removed from the concentrated gel, and the filter paper and PVDF membrane were activated with methanol and placed in the transfer buffer. Sequentially arranging filter paper, a PVDF film, gel and filter paper from the anode to the cathode, performing die rotation under the condition of constant current rotation for 1-2 h and current of 50-80 mA, and taking out the film for later use;
(6) blocking and immune response
The membrane was placed in 5% skim milk powder blocking solution (prepared with PBS buffer) and shaken gently for 2h at room temperature. Adding primary antibodies (Caspase-3, Caspase-9, I kappa B, PI3K, AKT, Bax, Bcl-2 and beta-actin), standing overnight at 4 deg.C, washing membrane, adding secondary antibody, incubating for 2h at room temperature on a shaker, and washing membrane;
(7) color development
The ECL luminescence solution was developed, the developer was developed for about 5min, and the fixing solution was fixed and then analyzed by Image J software. Carrying out quantitative analysis on target proteins, and correcting differences and changes of protein expression among groups by taking beta-actin as an internal reference;
(8) statistical method
Statistical analysis of experimental data was performed using SPSS17.0 software, data to
Showing that data between two groups were statistically analyzed by T-test, comparison between groups was statistically analyzed by one-way analysis of variance, p<0.05 is statistically significant.
As a result: the protein expression of Caspase-3 and Caspase-9 is determined by using a Western Blot method, and the experimental result shows that compared with a sham operation group, the protein expression of the model group Caspase-3 and Caspase-9 is obviously increased (p is less than 0.01), which indicates that the Caspase-3 and Caspase-9 are activated; compared with the model group, the expression of Caspase-3 and Caspase-9 can be obviously reduced in each dosage group of the rosewood composition, which shows that the rosewood composition inhibits the activation of Caspase-3 and Caspase-9, and the result is shown in figure 6. V
Example 12
Effect of lignum Dalbergiae Odoriferae composition group on the expression of Bax and Bcl-2 proteins in VaD model rat
The Western Blot method is used for determining the expression of rat apoptosis factors Bax and Bcl-2 proteins in each group, and the experimental result shows that compared with a sham operation group, the expression of the model group Bax is obviously increased, and the expression of the Bcl-2 is obviously reduced (P is less than 0.01); compared with the model group, the dalbergia wood composition up-regulates the anti-apoptosis factor Bcl-2 and down-regulates the pro-apoptosis factor Bax, which indicates that the expression of Bax and Bcl-2 protein can be regulated (P is less than 0.05).
Example 13
Effect of Dalbergia Odorifera composition on VaD model rat PI3K/Akt
The Western Blot method is used for measuring the protein expression of rat apoptosis factor PI3K/Akt of each group, and research shows that after the activation of PI3K, Akt can be induced to be activated, so that the survival of neuron cells is promoted, the apoptosis of the neuron cells is inhibited, and the brain protection effect is exerted. Western Blot experiment results show that the expression levels of PI3K and Akt in the brains of rats in a model group are obviously lower than those of a sham operation group, the two groups of experiments have statistical significance (P is less than 0.001), and compared with the model group, the expression levels of PI3K and Akt in the brains of a rosewood composition group are obviously increased, which indicates that the rosewood composition can play an anti-apoptosis role through an activated PI3K/Akt signal channel.
Claims (3)
1. A dalbergia wood composition is characterized in that: is prepared from the following raw materials in parts by weight: 10-30 g of dalbergia wood and 10-30 g of salvia miltiorrhiza.
2. A preparation method of a dalbergia wood composition is characterized by comprising the following steps: 10-30 g of dalbergia wood and 10-30 g of salvia miltiorrhiza, crushing dalbergia wood medicinal materials, and extracting dalbergia wood volatile oil by a water distillation method; crushing a salvia miltiorrhiza medicinal material, adding water which is 2-5 times of the weight of the salvia miltiorrhiza, soaking for 1-3 hours, performing reflux extraction for 1-3 times at 90-100 ℃, combining extracting solutions, concentrating, mixing the extracting solution, and mixing the dalbergia wood volatile oil and the salvia miltiorrhiza solution to obtain the traditional Chinese medicine composition, wherein each milliliter of the solution contains 1-3 g of crude drug of the dalbergia wood and 1-3 g of crude drug of the salvia miltiorrhiza.
3. The use of the dalbergia wood composition of claim 1 in the preparation of an anti-vascular dementia medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110027811.0A CN112807342A (en) | 2021-01-11 | 2021-01-11 | Dalbergia wood composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110027811.0A CN112807342A (en) | 2021-01-11 | 2021-01-11 | Dalbergia wood composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112807342A true CN112807342A (en) | 2021-05-18 |
Family
ID=75868568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110027811.0A Pending CN112807342A (en) | 2021-01-11 | 2021-01-11 | Dalbergia wood composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112807342A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857395A (en) * | 2006-03-17 | 2006-11-08 | 崔彬 | Compound Chinese medicine composition for treating cardiac and cerebral vascular diseases |
| CN1961911A (en) * | 2005-11-08 | 2007-05-16 | 天津药物研究院 | Lyophilized powder injection containing red sage root and dalbergia wood volatile oil and preparation method thereof |
| CN101023983A (en) * | 2006-02-23 | 2007-08-29 | 山东绿叶天然药物研究开发有限公司 | Medicine composition and use |
| CN101085013A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root, safflower, radix astragali and dalbergia oil and its preparation |
| CN101926849A (en) * | 2010-08-05 | 2010-12-29 | 北京师范大学 | Method for preparing compound salvia composition for treating heart cerebrovascular disease |
-
2021
- 2021-01-11 CN CN202110027811.0A patent/CN112807342A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1961911A (en) * | 2005-11-08 | 2007-05-16 | 天津药物研究院 | Lyophilized powder injection containing red sage root and dalbergia wood volatile oil and preparation method thereof |
| CN101023983A (en) * | 2006-02-23 | 2007-08-29 | 山东绿叶天然药物研究开发有限公司 | Medicine composition and use |
| CN1857395A (en) * | 2006-03-17 | 2006-11-08 | 崔彬 | Compound Chinese medicine composition for treating cardiac and cerebral vascular diseases |
| CN101085013A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root, safflower, radix astragali and dalbergia oil and its preparation |
| CN101926849A (en) * | 2010-08-05 | 2010-12-29 | 北京师范大学 | Method for preparing compound salvia composition for treating heart cerebrovascular disease |
Non-Patent Citations (1)
| Title |
|---|
| 张汤敏，等: "《老年痴呆中医防治》", 31 July 2002 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003227336B2 (en) | Composition for heart disease, method to prepare same and uses thereof | |
| CN102548571B (en) | Compositions and methods for prevention and treatment of brain diseases and conditions | |
| Li et al. | Antidepressant-like effects of the saponins extracted from Chaihu-jia-longgu-muli-tang in a rat unpredictable chronic mild stress model | |
| Zeng et al. | Xiaoyaosan ethyl acetate fraction alleviates depression-like behaviors in CUMS mice by promoting hippocampal neurogenesis via modulating the IGF-1Rβ/PI3K/Akt signaling pathway | |
| CN103257188A (en) | Construction method for compound thrombus clearing preparation bioactivity chromatography finger print | |
| Wan et al. | Neuroprotection, learning and memory improvement of a standardized extract from Renshen Shouwu against neuronal injury and vascular dementia in rats with brain ischemia | |
| Sim et al. | Protective effects of a herbal extract combination of Bupleurum falcatum, Paeonia suffruticosa, and Angelica dahurica against MPTP-induced neurotoxicity via regulation of nuclear receptor-related 1 protein | |
| Cao et al. | YiQiFuMai powder injection ameliorates blood–brain barrier dysfunction and brain edema after focal cerebral ischemia–reperfusion injury in mice | |
| Shi et al. | Danggui-Shaoyao-San improves cognitive impairment through inhibiting O-GlcNAc-modification of estrogen α receptor in female db/db mice | |
| CN104225524A (en) | Application of trichosanthes kirilowii maxim and cassia twig decoction in preparing medicament for treating or/and preventing cognitive impairment | |
| Pan et al. | Bushen Jieyu Tiaochong Formula reduces apoptosis of granulosa cells via the PERK-ATF4-CHOP signaling pathway in a rat model of polycystic ovary syndrome with chronic stress | |
| Ma et al. | Mingmu Xiaoyao granules regulate the PI3K/Akt/mTOR signaling pathway to reduce anxiety and depression and reverse retinal abnormalities in rats | |
| Tong et al. | Saikosaponin a activates tet1/dll3/notch1 signalling and promotes hippocampal neurogenesis to improve depression-like behavior in mice | |
| Jin et al. | Neuroprotective effects of Korean White ginseng and Red ginseng in an ischemic stroke mouse model | |
| WO2022121986A1 (en) | Novel medicament for preventing and treating neurodegenerative diseases | |
| Zhang et al. | Mechanisms and status of research on the protective effects of traditional Chinese medicine against ischemic brain injury | |
| min Luo et al. | Tibetan medicine Ru-yi-Zhen-bao Pills exhibits anti-migraine effect through mediating PAG anti-nociceptive channel | |
| Yan et al. | Xi-Xian-Tong-Shuan capsule alleviates vascular cognitive impairment in chronic cerebral hypoperfusion rats by promoting white matter repair, reducing neuronal loss, and inhibiting the expression of pro-inflammatory factors | |
| Xu et al. | Efficacy of curculigoside in protecting against ischemic brain injury through regulation of oxidative stress and NF-κB and PI3K/Akt expression | |
| Hua et al. | Tong-Qiao-Huo-Xue decoction activates PI3K/Akt/mTOR pathway to reduce BMECs autophagy after cerebral ischemia/reperfusion injury | |
| CN102233009B (en) | Chinese medicinal composition for promoting nerve regeneration and preparation method and use thereof | |
| Wu et al. | Levomilnacipran improves lipopolysaccharide-induced dysregulation of synaptic plasticity and depression-like behaviors via activating BDNF/TrkB mediated PI3K/Akt/mTOR signaling pathway | |
| Song et al. | LiuweiDihuang improved cognitive functions in SAMP8 mice by inhibiting COX-2 expression and subsequent neuroinflammation | |
| CN112807342A (en) | Dalbergia wood composition and application thereof | |
| CN102526656A (en) | Medicament or health-care food composition for preventing or/and treating erythremia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210518 |